NCT00999830View on ClinicalTrials.gov

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

IPH2101

One infusion of IPH2101 every 4 weeks

Trial Locations (9)

13273

Institut Paoli Calmettes, Marseille

14033

C.H.R.U. de Caen - Hôpital Bretonneau, Caen

21079

CHU Dijon, Dijon

37044

C.H.R.U. de Tours, Tours

54511

CHU Nancy, Nancy

59037

CHRU Lille, Lille

75010

Hopital Saint Louis, Paris

75012

Hôpital Saint Antoine, Paris

87042

Hôpital Dupuytren, Limoges

Sponsors

Lead Sponsor

Innate Pharma
All Listed Sponsors
lead

Innate Pharma

INDUSTRY